ICCVAM Skin Sensitization Working Group Activities

June 25, 2014
SSWG Scope and Charge

• Fostering the evaluation and promotion of alternative test methods for regulatory use in skin sensitization hazard assessment has been one of ICCVAM’s long-standing priorities. ICCVAM is committed toward continued work in this area and believes it has promise for the near-term development of testing strategies that do not require the use of animals.

• As ICCVAM’s goal is to advance the state of the science for alternative test methods and testing strategies for skin sensitization, the ICCVAM skin sensitization working group has been established to provide expertise in the evaluation of the following activities:
Work Group Activities

1. The consideration of criteria for ICCVAM acceptance of ECVAM individually validated methods in the area of skin sensitization.

2. The design and examination of the predictive value of a battery of EVCAM validated methods and of in silico methods (e.g., QSAR predictions) based on statistical methods.
3. A review of the Cosmetics Europe recommended battery for dermal sensitization, based on Cosmetics Europe’s review of 16 non-animal methods.

4. Disposition of the NIOSH Electrophilic Allergen Screening Assay (EASA) nomination.
EURL ECVAM Validation/Recommendations

• Direct Peptide Reactivity Assay (DPRA, Procter & Gamble)
  – Uses HPLC to monitor chemical depletion of nucleophile-containing synthetic peptides
  – EURL ECVAM recommendations published Nov 2013

• Myeloid U937 Skin Sensitization Test (MUSST; L’Oréal)
  – Flow cytometry detection of induced surface protein marker in human monocytic cell line
  – Interlaboratory testing Phase B1 completed (9 coded substances)
  – VMG recommended further protocol development due to interlaboratory variability

• Human Cell Line Activation Test (h-CLAT; Kao, and Shiseido)
  – Flow cytometry detection of 2 induced surface protein markers in human monocytic leukemia cell line
  – Interlaboratory reproducibility testing completed (24 coded substances, 4 labs)
  – EURL ECVAM recommendations expected 2014

• KeratinoSens™
  – Is a reporter gene assay measuring activation of the Keap1-Nrf2-ARE signaling pathway. Measures luciferase activity via luminescence
  – EURL ECVAM recommendations published Feb 2014
Integrated Testing Strategy

Because the adverse outcome pathway is well-characterized, and a number of non-animal test methods have been developed, it has promise for the near-term development of testing strategies that do not require the use of animals.
Skin Sensitization Process

INDUCTION

1. Skin Penetration, Electrophilic, Low MW

2. Langerhans Cell (LC)

3. Migration to local lymph node

4. ICAM-1

5. T-cell proliferation

ELICITATION

6. IL-1β, IL-6, IL-12, IL-18

7. TNF-α, GM-CSF

8. Keratinocytes

9. Edema and erythema

10. Cellular influx

11. Cytokines, costimulatory, adhesion molecules increase

12. Specific inflammatory response

13. "Primed" lymphocytes

*Illustration by D. Sailstad
ICCVAM Proposal

• Produce and test an integrated decision strategy for skin sensitization using
  – Physicochemical parameters
  – An *in silico* method
  – The three *in chemico* or *in vitro* assays validated by EURL ECVAM

• Design the integrated decision strategy to predict skin sensitization (yes/no) based on LLNA results
Outline

• Physicochemical Parameters
  – Log Kow – octanol:water coefficient
  – Rationale: related to the ability to penetrate the skin; used in a number of bioavailability models and skin sensitization models

• In Silico Method
  – OECD QSAR Toolbox http://www.qsartoolbox.org/;
  – Recommended by the European Chemicals Agency for making chemical categories for read-across predictions (filling data gaps) to support chemical registrations
  – Can simulate metabolites
  – Uses mechanistic and structural features to group chemicals into categories
Proposed *In Chemico* and *In Vitro* Methods

- Direct peptide reactivity assay (DPRA)
- Human cell line activation test (h-CLAT)
- KeratinoSens™

**Rationale**

- Completed or nearly completed pre-validation and peer review process at EURL ECVAM
- OECD test guidelines for DPRA and KeratinoSens™ will be finalized in 2014; h-CLAT will follow
- Covers 3 key events of the AOP
OECD Adverse Outcome Pathway (AOP) for Skin Sensitization

For sensitization that is initiated by covalent binding to proteins.

http://www.oecd.org/chemicalsafety/testing/seriesontestingandassessmentpublicationsbynumber.htm
Outline

• Selection of chemicals
  – NICEATM has identified 123 substances with DPRA, h-CLAT, KeratinoSens, and LLNA data.
  – Characterize by: physicochemical characteristics, such as structure, LogKow; range of LLNA potency
  – Evaluate relevance to applicability domain of the in chemico/in vitro assays
  – Split database into training set to build models and a test set to test the models
Statistical Methods

• Bayesian networks have been used to predict LLNA potency category

• Artificial neural network, a computational model that can compute values from inputs by feeding information through the network. Has been used to predict LLNA thresholds using h-CLAT and measurement of cell surface thiols.

• Support vector machine analyzes data and recognizes patterns. Is non-probabilistic. Has been used to build QSAR models to predict LLNA and guinea pig results; also used to predict LLNA sensitizer/nonsensitizers using gene expression results from the Genomic Allergen Rapid Detection (GARD) assay.

• Logistic regression, linear discrimination analysis, simple battery approach
Cosmetics Europe Activity

• Developing data integration strategy
  – Predictive compared to LLNA and/or humans
  – Relevant for 5-6 potency classes

• Prioritized 8 methods for testing 100 chemicals
  – DPRA, PPRA, KeratinoSens, Lu-Sens, SENS-IS (Immunosearch), MUSST, h-CLAT, and VITO-SENS
  – Additional methods will be evaluated as funding is acquired
EASA

- Nominated by Dr. Paul Siegel, NIOSH, in 2012
  - Mechanistically similar to the DPRA
  - Identifies electrophilic allergens that react with nucleophilic amino acids to form stable covalent bond
  - Binding to protein is the molecular initiating event in the Adverse Outcome Pathway (AOP) leading to skin sensitization response
- A preliminary evaluation was performed by NICEATM
- The Immunotoxicity Working Group and SACATM gave the test method a high priority for a validation study
- ICCVAM gave the EASA a conditional high priority pending feedback that the work is not duplicating efforts in Europe
Comments and/or Questions?